Clinical trials: Chronic Obstructive Airways Disease Exacerbated
Chronic Obstructive Pulmonary Disease (COPD)
2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients
The aim of the present study is to evaluate the superiority of the fixed triple therapy with BDP/FF/GB at a daily dose of 400/24/50 mcg respectively with that of Ultibro® Breezhaler® (DPI), fixed combination of indacaterol 85 mcg…
- Trial name
- TRIBUTE (NCT02579850)
- Testing
- Central spirometry, COPD assessment test, Local laboratory Assessments
- Where
- Italy
- Volunteers
- 1,532 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Effects of COPD Standardized Management on COPD Exacerbation
This is a multi-center, parallel-group,cluster randomised trial involving secondary hospitals across China. The objective is to evaluate the effect of COPD on reducing moderate-to-severe exacerbations during 12 months follow-up…
- Trial name
- COPD STANDARD (NCT04664491)
- Testing
- Standardized COPD management, Routine COPD management
- Where
- China
- Volunteers
- 3,456 people
- Sponsor
- China-Japan Friendship Hospital
Chronic Obstructive Pulmonary Disease
Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China
Chronic obstructive pulmonary disease (COPD) is one of the commonest respiratory diseases. During the early stage of COPD, patients only have mild respiratory symptoms or signs which may lead to under-diagnosis of the disease.
- Trial name
- Tie-COPD (NCT01455129)
- Testing
- Tiotropium
- Where
- 25 sites in China
- Volunteers
- 841 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
COPD Exacerbation Acute
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation.
- Trial name
- NCT05400369
- Testing
- Sitafloxacin, Moxifloxacin Hydrochloride
- Where
- 18 sites in China
- Volunteers
- 140 people
- Sponsor
- Daiichi Sankyo
COPD Exacerbation, Pneumonia
Comparison of Multiple Oxygenation Targets With Different Oximeters in Chronic Obstructive Pulmonary Disease (COPD) and Non-COPD Patients- Impact on Oxygen Flows
The oximeter is an instrument for monitoring patients receiving oxygen therapy. It displays pulse oxygen saturation (SpO2), which is a reflection of arterial oxygen saturation (SaO2).
- Conditions
- COPD Exacerbation, Pneumonia, Hypoxemia, Respiratory Disease
- Trial name
- NCT05819164
- Testing
- Masimo oximeter, Nellcor oximeter, Nonin oximeter
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Laval University
COPD, COPD Exacerbation
Isolation of Circulating Pulmonary Cells in COPD and Its Relationship With Clinical Relevant Outcomes (IbICEnCa)
We have demonstrated for the very first time that it is possible to isolate CPCs (circulating pulmonary cells) in patients with COPD in a sample of 17 patients (with a recovery rate of nearly 40%) and none of 10 healthy, non…
- Conditions
- COPD, COPD Exacerbation, COPD, Severe Early-Onset
- Trial name
- IbICEnCa (NCT03591978)
- Testing
- Isolation of Circulating Pulmonary Cells in peripheral blood
- Where
- 4 sites in Spain
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Universidad de Granada
COPD Exacerbation
Effect of Home Based Pulmonary Rehabilitation on Exacerbation and Hospital Admission in Severe COPD
The study is a randomized controlled trial. The cases will be divided into two groups as the Homespirometer group and the control group.
- Trial name
- NCT05738720
- Testing
- Teknikel Spirobank Home Type Respiratory Function Tester (Homespirometer), Exercise Programme
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- Saglik Bilimleri Universitesi
COPD Exacerbation
HFNC vs Nasal Cannula in Mild Chronic Obstructive Pulmonary Disease Exacerbation
For AECOPD patients, only 8% patients ventilated by noninvasive and invasive positive pressure ventilation. Nasal cannula is the most common pattern of oxygen therapy in mild AECOPD.
- Trial name
- NCT03003559
- Testing
- High flow nasal cannula
- Where
- China
- Volunteers
- 328 people
- Sponsor
- China-Japan Friendship Hospital
SAA Level and SAA/Lipoxin A4 Ratio
Evaluation of Biomarkers of COPD Exacerbation
Serum amlyoid A (SAA) was shown to act as biomarker for exacerbation of chronic obstructive pulmonary disease (AE-COPD). It seems that SAA triggers chronic inflammation by binding to ALX/PFR2 receptor.
- Trial name
- NCT03609541
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Heidelberg University
COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation Chronic Obstructive Pulmonary Disease
Muscle Oxygenation in Patients With COPD Exacerbation
Chronic obstructive pulmonary disease (COPD) is often complicated by acute exacerbations, which lead to functional impairments, increased dyspnea, and a rapid decline in lung function.
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation Chronic Obstructive Pulmonary Disease, Muscle Oxygenation
- Trial name
- NCT07801547
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Hacettepe University
COPD Exacerbation
Telehealth Pulmonary Rehabilitation for Hispanic and African-American Patients Admitted With Exacerbation of COPD
Chronic Obstructive Pulmonary Disease (COPD), also known as emphysema, is the leading cause of hospitalization for older adults in the U.S., and a leading cause of death.
- Trial name
- NCT03007485
- Testing
- Telehealth Pulmonary Rehabilitation
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Northwell Health
COPD Exacerbation
Early Assisted Discharge for COPD Exacerbations With Telemonitoring.
To determine if an early assisted discharge program for acute exacerbations of COPD (AECOPD), with telemonitoring and telephone control, is equally effective and more efficient in terms of use of health care resources, that a…
- Trial name
- NCT01951261
- Testing
- Telemonitoring and telephone control
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Dr. López Viña
COPD, COPD Exacerbation
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
Investigators propose to develop methods to improve early identification of acute exacerbations of COPD (AECOPD) among HIV-infected individuals.
- Trial name
- mReach (NCT01892566)
- Testing
- mHealth Intervention
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Extracorporeal Carbon Dioxide Removal Plus Noninvasive Ventilation in Patients With COPD Not Eligible for Intubation
This study will evaluate whether adding extracorporeal carbon dioxide removal (ECCO2R) to noninvasive ventilation can improve breathing in adults hospitalized with a severe worsening of chronic obstructive pulmonary disease…
- Trial name
- NCT07785375
- Testing
- Extracorporeal Carbon Dioxide Removal, Noninvasive Ventilation
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Hospital del Mar Research Institute (IMIM)
Pollution; Exposure, Chronic Obstructive Pulmonary Disease
Air Pollution and COPD Exacerbation
There is an excess of hospitalization rates for acute exacerbation of COPD in Picardy compared to the national data. A first study realized in Picardy has shown a link between air quality and COPD.
- Trial name
- BePoPi (NCT03904875)
- Testing
- collection of data about each acute exacerbation of COPD
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
COPD
ICE COPD PikoLogic® Cohort Study.Implementation, Compliance, and Effectiveness of Integrating the PikoLogic®
This is a two-step observational cohort study evaluating the impact of adding PikoLogic® to the current disease management COPD discharge protocol subsequent to an admission for COPD exacerbation.
- Trial name
- ICE (NCT02341157)
- Sponsor
- University of Louisville
Copd Exacerbation Acute, Readmission
Identification of Patients Admitted With COPD Exacerbations and Predicting Readmission Risk Using Machine Learning
Patients with Chronic Obstructive Pulmonary Disease (COPD) who are admitted to hospital are at high risk of readmission. While therapies have improved and there are evidence-based guidelines to reduce readmissions, there are…
- Conditions
- Copd Exacerbation Acute, Readmission, Machine Learning, Natural Language Processing
- Trial name
- NCT04192175
- Where
- Canada
- Volunteers
- 65,000 people
- Sponsor
- University Health Network, Toronto
Chronic Obstructive Pulmonary Disease (COPD)
Exacerbation Self-management in COPD: The ACCESS Study
Aim is to test the effect of ACCESS ("Adaptive Computerized COPD Exacerbation Self-management Support"), a software application designed to support patients with COPD in self-management of exacerbations.
- Trial name
- ACCESS (NCT02553096)
- Testing
- ACCESS
- Where
- Netherlands
- Volunteers
- 87 people
- Sponsor
- Radboud University Medical Center
ARF Secondary to COPD Exacerbation, ARF Secondary to Cardiogenic Acute Pulmonary Oedema
HERMES STUDY: Study on the Feasibility and Efficiency of Noninvasive Positive-Pressure Ventilation (NPPV) in Prehospital Care
The purpose of this study is determine if NPPV can be performed in a pre-hospital setting very early after onset of dyspnea with a similar benefit in need of intubation and mortality as in previous study in hospital context and…
- Trial name
- NCT00375154
- Testing
- Noninvasive Positive-Pressure Ventilation (NPPV)
- Where
- 8 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Chronic Obstructive Pulmonary Disease (COPD)
Tezepelumab COPD Exacerbation Study
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- COURSE (NCT04039113)
- Testing
- Tezepelumab
- Where
- 91 sites in United States, Canada and 8 more
- Volunteers
- 337 people
- Sponsor
- AstraZeneca